Table 1. Patient characteristics.
N=75 | |
---|---|
Age: median (range) |
60 (34–93) |
Gender % (N) | |
Male | 29.3 (22) |
Female |
70.7 (53) |
Race % (N) | |
White | 22.7 (17) |
Hispanic | 32.0 (24) |
Black | 41.3 (31) |
Other |
4.0 (3) |
Diagnosis % (N) | |
Stage IV | 46.7 (35) |
Recurrence |
53.3 (40) |
Site of primary % (N) | |
Colon | 73.3 (55) |
Rectum |
26.7 (20) |
Sites of disease % (N) | |
Liver only | 24.0 (18) |
Other sites |
76.0 (57) |
Number of metastatic sites: median (range) |
3 (1–6) |
Differentiation % (N) | |
Well | 16 (12) |
Moderately | 54.7 (41) |
Poorly | 20.0 (15) |
Unknown |
9.3 (7) |
CEA at diagnosis of stage IV, median (range) |
24.5 (0.5–5500) |
Number of chemo lines % (N) | |
1 | 20.0 (15) |
2 | 40.0 (30) |
3 | 33.3 (25) |
4 | 5.3 (4) |
5 |
1.3 (1) |
KRas status % (no.) | |
Mutant | 42.67 (32) |
WT | 57.33 (43) |
Abbreviations: CEA=carcinoembryonic antigen; WT=wild type.
The table depicts clinical characteristics of the 75 patients who were included in this study.